



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,104	01/27/2004	Woonza M. Rhee	112129.403C5	2188
41551	7590	05/12/2009		
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC			EXAMINER	
701 FIFTH AVENUE, SUITE 5400			FUBARA, BLESSING M	
SEATTLE, WA 98104-7092			ART UNIT	PAPER NUMBER
			1618	
MAIL DATE		DELIVERY MODE		
05/12/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/766,104	Applicant(s) RHEE ET AL.
	Examiner BLESSING M. FUBARA	Art Unit 1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 17 February 2009.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-16,19-22,25-47,50,53-56 and 59-81 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-16,19-22,25-47,50,53-56 and 59-81 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date: _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date: _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Examiner acknowledges receipt of request for extension of time, request for continued examination under 37 CFR 1.114, amendments and remarks filed, all 2/17/09. Claims 1, 35 and 73 are amended. Claims 82-84 canceled. Claims 1-16, 19-22, 25-47, 50, 53-56 and 59-81 are pending.

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/17/09 has been entered.

Response to Arguments

Previous rejections that are not reiterated herein are withdrawn.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless —

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 1-16, 19, 20, 25, 29, 31, 35, 36-47, 50, 53, 54, 59, 61, 70 and 72 rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Rhee et al. (US 5,162,430).

4. Claims 1, 35 and 73 have been amended to recite “synthetic polypeptide or poly(alkylene oxide).” However, synthetic polypeptide is a genus of polypeptides and since the collagen, a polypeptide, has been chemically conjugated to PEG in Rhee, the Collagen-dPEG no longer is a natural polypeptide but meets the limitation of synthetic polypeptide.

Rhee repairs tissues such as nose, ear, knee, larynx, tracheal rings; or replace tendon, ligament and blood vessel tissue by applying a mixture of collagen -dPEG (column 12, lines 49-61). The PEG used in Rhee can also be activated as succinimidyl monomethylpolyethylene glycol (column 9, lines 1-6) and the succinimidyl ester PEG is capable of reacting with free amino groups as it does with the lysine residues of collagen (column 9, lines 6-10). The collagen-dPEG meets the limitation of synthetic polypeptide of claims 1, 35 and 73 while the succinimidyl activated PEG meets the limitations of second precursors having different groups, nucleophilic and electrophilic groups as required by claims 1-16, 19, 20, 25, 29, 35-47, 50, 53, 54, 59, 63, 70 and 72. The reaction of the activated PEG and the collagen appears to occur at about pH of 7 (column 9, line 60) meeting claims 27, 31 and 61. Rhee contemplates using molar excess of the activated PEG (column 10, line 2) meeting claims 33, 34, 67 and 68. Rhee contemplates an embodiment in which the mixture can be administered to the site before cross-linking is completed (column 7, lines 60-67; column 11, lines 60-64) meeting the requirement that claims 1, 35 and 73 (under 35 USC 103). While Rhee does not specifically state that the two solutions are separately applied, the two solutions are mixed and applied and polymerization

Art Unit: 1618

and cross-linked in situ. Rhee teaches that the composition is administered to augment or repair soft or hard tissue (column 6, lines 28-46) meeting the methods of the claims.

Rhee teaches collagen that is chemically conjugated to PEG and since collagen is rich in amino acids such as lysine, proline, hydroxylysine and hydroxyproline; and since that amino acids most likely present on the collagen are the lysine, proline, hydroxylysine and hydroxyproline , Rhee's synthetic polymer contains amino functional groups. The succinimidyl meets claims 19 and 20. Cross-linking of the first and second precursor molecules takes place in situ meeting the method steps of claims 1-5 and the nucleophilic and electrophilic groups on the first and second precursor meet claims 6-16. Therefore, the claims are met.

In the alternate, while Rhee teaches that cross-linking takes place in situ. but, if the order of the method steps differs, changes in the sequence of adding ingredients is not patentable over the method steps of Rhee and selection of any order of performing process steps is prima facie obvious in the absence of unexpected results. Therefore, taking the teachings of Rhee, one having ordinary skill in the art at the time the invention was made would follow the method steps of Rhee to apply the cross-linking precursors to the desired site where polymerization will take place to effect the expected augmentation of the tissue.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

7. Claims 1-16, 19-22, 25-47, 50, 53-56 and 59-84 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rhee et al. (US 5,162,430) in view of Jiang et al. (US 5,505,952).

8. Claims 1, 35 and 73 have been amended to recite “synthetic polypeptide or poly(alkylene oxide).” However, synthetic polypeptide is a genus of polypeptides and since the collagen, a polypeptide, has been chemically conjugated to PEG in Rhee, the Collagen-dPEG no longer is a natural polypeptide but meets the limitation of synthetic polypeptide.

Rhee has been described above to anticipate or render obvious claims 1-16, 19, 20, 25, 29, 31, 35, 36-47, 50, 53, 54, 59, 61, 70 and 72. The collagen-dPEG meets the limitation of synthetic polypeptide of claims 1, 35 and 73 while the succinimidyl activated PEG meets the limitations of second precursors having different groups, nucleophilic and electrophilic groups as required by claims 1-16, 19, 20, 25, 29, 35-47, 50, 53, 54, 59, 63, 70, 72-77, 79-81. The reaction of the activated PEG and the collagen appears to occur at about pH of 7 (column 9, line 60) meeting claims 27, 31, 61 and 65. The concentrations/amounts recited in claims 26, 28, 30, 32, 60, 62, 64 and 66 would not patentably distinguish the claimed invention over the prior art in the absence of factual showing. Rhee contemplates using molar excess of the activated PEG

(column 10, line 2) meeting claims 33, 34, 67 and 68. Rhee contemplates an embodiment in which the mixture can be administered to the site before cross-linking is completed (column 7, lines 60-67; column 11, lines 60-64) meeting the requirement that claims 1, 35 and 73. The two solutions in Rhee are mixed and applied and polymerization and cross-linked in situ. Rhee teaches that the composition is administered to augment or repair soft or hard tissue (column 6, lines 28-46) meeting the methods of the claims.

Rhee teaches collagen that is chemically conjugated to PEG and since collagen is rich in amino acids such as lysine, proline, hydroxylysine and hydroxyproline; and since that amino acids most likely present on the collagen are the lysine, proline, hydroxylysine and hydroxyproline , Rhee's synthetic polymer contains amino functional groups. The succinimidyl meets claims 19 and 20. Cross-linking of the first and second precursor molecules takes place in situ meeting the method steps of claims 1-5 and the nucleophilic and electrophilic group on the first and second precursor meet claims 6-16.

However, while the amine groups on collagen are primarily lysine, proline, hydroxylysine and hydroxyproline, Rhee does not state that the nucleophilic groups could be thiols. But compositions containing polyamino acid polymers such as polylysine and those having methionine and cysteine have been shown in the prior art to be used to promote tissue repair or tissue growth according to Jiang at column 2, lines 54-64 and Example 1. The presence of methionine or cysteine meets claims 21, 22, 55, 5 and 78. Therefore, taking the teachings of the references together, one having ordinary skill in the art at the time the invention was made would have reasonable expectation of success that combining the activated succinimidyl PEG with the polylysine polymer would lead to reaction of the ester functionality of the activated PEG and the

amino group of the lysine which when administered to the tissue site would cross-link and act to augment the tissue. One of ordinary skill in the art at the time the invention was made would have reasonable expectation of success to augment soft tissue by administering the individual composition to the tissue site requiring augmentation in order for the two compositions to advantageously polymerize at the sites needing augmentation.

Response to Arguments

9. Applicant's arguments filed 2/17/09 as it relates to the current rejections have been fully considered but they are not persuasive.
10. Applicant argues Rhee does not teach synthetic polymer because collagen is a natural polymer. The examiner disagrees because once the collagen is conjugated to form a chemically modified polymer., it ceases to be natural polymer. Thus Rhee teaches synthetic polypeptide.
11. With respect to the Interview of 2/4/2009, the examiner has fully considered the claims and finds that the claims are not allowable. And with respect to the citation of new matter in the claims as it refers to the deletion of "*" form formula (I), it is noted that there is noting unusual about change in examiners viewpoint.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLESSING M. FUBARA whose telephone number is (571)272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Blessing M. Fubara/
Examiner, Art Unit 1618